These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 27643491

  • 1. Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort.
    Ishikawa Y, Fujii T, Ishikawa SK, Yukawa N, Hashimoto M, Furu M, Ito H, Ohmura K, Mimori T.
    PLoS One; 2016; 11(9):e0162896. PubMed ID: 27643491
    [Abstract] [Full Text] [Related]

  • 2. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 3. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I, Bobbio-Pallavicini F, Franceschini F, Bazzani C, Ceribelli A, Bravi E, Zingarelli S, Caporali R, Cattaneo R, Montecucco CM.
    Clin Exp Rheumatol; 2007 Mar; 25(5):676-83. PubMed ID: 18078613
    [Abstract] [Full Text] [Related]

  • 13. [IgG-type antihistone antibodies. Diagnostic value in rheumatoid polyarthritis, scleroderma, spontaneous and drug-induced lupus].
    Meyer O, Cyna L, Haïm T, Ryckewaert A.
    Rev Rhum Mal Osteoartic; 1984 Jun; 51(6):303-10. PubMed ID: 6382565
    [Abstract] [Full Text] [Related]

  • 14. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C.
    Arthritis Res Ther; 2004 Jun; 6(3):R264-72. PubMed ID: 15142273
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation.
    Novak S, Anić B, Anić F, Cerovac M, Cikeš N.
    Acta Dermatovenerol Croat; 2011 Jun; 19(3):156-60. PubMed ID: 21933639
    [Abstract] [Full Text] [Related]

  • 16. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis.
    Russo K, Hoch S, Dima C, Varga J, Teodorescu M.
    J Rheumatol; 2000 Jan; 27(1):142-8. PubMed ID: 10648030
    [Abstract] [Full Text] [Related]

  • 17. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
    Svenson M, Geborek P, Saxne T, Bendtzen K.
    Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
    [Abstract] [Full Text] [Related]

  • 18. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis.
    Hoshino M, Yoshio T, Onishi S, Minota S.
    Mod Rheumatol; 2012 Aug; 22(4):532-40. PubMed ID: 22173229
    [Abstract] [Full Text] [Related]

  • 19. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 20. Antibody against chromatin assembly factor-1 is a novel autoantibody specifically recognized in systemic lupus erythematosus.
    Doe K, Nozawa K, Hiruma K, Yamada Y, Matsuki Y, Nakano S, Ogasawara M, Nakano H, Ikeda T, Ikegami T, Fujishiro M, Kawasaki M, Ikeda K, Amano H, Morimoto S, Ogawa H, Takamori K, Sekigawa I, Takasaki Y.
    Lupus; 2014 Sep; 23(10):1031-41. PubMed ID: 24836587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.